✦ LIBER ✦

Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer: An Eastern Cooperative Oncology Group study

Book ID: 122083538
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 137 KB
Volume: 12
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(95)96460-D

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of oral etoposide plus ci

Phase II trial of oral etoposide plus cisplatin in extensive stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study

✍ Schiller, Joan H.; Ettinger, David S.; Larson, Marilyn M.; Gradishar, William; M 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 516 KB

Phase II trial of high-dose cisplatin pl

Phase II trial of high-dose cisplatin plus etoposide plus vinblastine in non-small-cell lung cancer. A hoosier oncology group study

📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 160 KB

An Overview of Eastern Cooperative Oncol

An Overview of Eastern Cooperative Oncology Group Stage III Non-Small Cell Lung Cancer Studies

✍ David S. Ettinger 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Phase II study of ifosfamide, carboplati

Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group pilot study

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 276 KB

Long-term survivors in metastatic non-sm

Long-term survivors in metastatic non-small-cell lung cancer: An eastern cooperative oncology group study

📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 179 KB

A Phase II study of all-trans-retinoic a

A Phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma : An Eastern Cooperative Oncology Group study

✍ Gregory P. Kalemkerian; Michael Jiroutek; David S. Ettinger; John A. Dorighi; Da 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.